key: cord-0694540-nut0u0ux
authors: Landolf, Kaitlin M.; Lemieux, Steven M.; Rose, Christina; Johnston, Jackie P.; Adams, Christopher D.; Altshuler, Jerry; Berger, Karen; Dixit, Deepali; Effendi, Muhammad K.; Heavner, Mojdeh S.; Lemieux, Diana; Littlefield, Audrey J.; Nei, Andrea M.; Owusu, Kent A.; Rinehart, Marisa; Robbins, Blake; Rouse, Ginger E.; Thompson Bastin, Melissa L.
title: Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID‐19): A systematic review
date: 2021-10-28
journal: Pharmacotherapy
DOI: 10.1002/phar.2637
sha: 2894cbf629de5eabebf6eb5148adb299d4fff7b1
doc_id: 694540
cord_uid: nut0u0ux

Data regarding the use of corticosteroids for treatment of acute respiratory distress syndrome (ARDS) are conflicting. As the coronavirus disease 2019 (COVID‐19) pandemic progresses, more literature supporting the use of corticosteroids for COVID‐19 and non‐COVID‐19 ARDS have emerged. Glucocorticoids are proposed to attenuate the inflammatory response and prevent progression to the fibroproliferative phase of ARDS through their multiple mechanisms and anti‐inflammatory properties. The purpose of this systematic review was to comprehensively evaluate the literature surrounding corticosteroid use in ARDS (non‐COVID‐19 and COVID‐19) in addition to a narrative review of clinical considerations of corticosteroid use in these patient populations. OVID Medline and EMBASE were searched. Randomized controlled trials evaluating the use of corticosteroids for COVID‐19 and non‐COVID‐19 ARDS in adult patients on mortality outcomes were included. Risk of bias was assessed with the Risk of Bias 2.0 tool. There were 388 studies identified, 15 of which met the inclusion criteria that included a total of 8877 patients. The studies included in our review reported a mortality benefit in 6/15 (40%) studies with benefit being seen at varying time points of mortality follow‐up (ICU survival, hospital, and 28 and 60 days) in the COVID‐19 and non‐COVID‐19 ARDS studies. The two non‐COVID19 trials assessing lung injury score improvements found that corticosteroids led to significant improvements with corticosteroid use. The number of mechanical ventilation‐free days significantly were found to be increased with the use of corticosteroids in all four studies that assessed this outcome. Corticosteroids are associated with improvements in mortality and ventilator‐free days in critically ill patients with both COVID‐19 and non‐COVID‐19 ARDS, and evidence suggests their use should be encouraged in these settings. However, due to substantial differences in the corticosteroid regimens utilized in these trials, questions still remain regarding the optimal corticosteroid agent, dose, and duration in patients with ARDS.

Prior to the coronavirus disease 2019 (COVID-19) pandemic, approximately 10% of patients presenting to the intensive care unit (ICU) were admitted for acute respiratory distress syndrome (ARDS). 1 This estimate has increased subsequent to the pandemic with approximately 33% of patients with COVID-19 developing ARDS. 2, 3 ARDS is a hypoxemic state caused by an inflammatory process have been explored as a treatment for ARDS due to their antiinflammatory and anti-fibrotic properties, however, their use in improving clinically meaningful outcomes remains controversial. [6] [7] [8] Herein, we provide a comprehensive review of the literature regarding corticosteroid use in non-COVID-19 and COVID-19 ARDS in addition to a narrative review of clinical considerations for these patient populations.

Glucocorticoids have potent anti-inflammatory and immunomodulating effects via non-genomic and genomic mechanisms ( Figure 2 ).

Cytosolic glucocorticoid-glucocorticoid receptor (GC-GR) complexes directly modulate the transcription of glucocorticoid response elements and inhibit transcription factors nuclear factor-κB (NF-κB) and activating protein-1. 9,10 Through these mechanisms, glucocorticoids attenuate the production of pro-inflammatory cytokines. 11 They also work synergistically with natural antiinflammatory cytokines, including IL-4, -10, and -13 and increase the expression of IL-1 receptor antagonist. 12 Glucocorticoids have inhibitory effects on fibrin pathways including inhibition of fibroblast proliferation and collagen deposition through inhibition of cytokines. 13 They stimulate T-cell, eosinophil, and monocyte apoptosis that may naturally work to decrease inflammation in ARDS and inhibit neutrophil activation that may otherwise potentiate inflammation in ARDS. It is postulated that relative glucocorticoid deficiency and unchecked inflammation further worsens inflammation in the setting of ARDS. Through the above mechanisms, K E Y W O R D S acute respiratory distress syndrome, corticosteroids, COVID-19, mechanical ventilation F I G U R E 1 Actions of Corticosteroids in Acute Respiratory Distress Syndrome (ARDS). Panel A depicts a normal alveolus with intact alveolar cell structures and vascular epithelial membrane. Panel B shows alveolar changes following an acute inflammatory insult. Corticosteroids mitigate multiple pathways in the acute state. (1) Reduce extravasation of plasma through the intercellular junction. (2) Inhibit adhesion of neutrophils to the endothelial cell and migration across the capillary wall to into the alveoli. (3) Modulation of proinflammatory cytokines through genomic and non-genomic pathways. (4) Inhibition of fibroblast proliferation and collagen disposition F I G U R E 2 Pharmacology of Glucocorticoids. NF-κB, nuclear factor-kappa B, Hsp, heat shock protein, IκB, inhibitor-kappa B. The three main pathways of glucocorticoid pharmacology include DNA-dependent regulation of anti-inflammatory proteins, non-genomic modulation of inflammation, and direct protein interference of transcription factors such as nuclear factor-kappa B (NF-κB). Corticosteroids diffuse across cell membranes and bind with cytosol-bound glucocorticoid receptors. Activated glucocorticoid-glucocorticoid receptor (GC-GR) complexes trigger both non-genomic and genomic pathways. In the nucleus, the GC-GR complex dimerizes and activates glucocorticoidresponsive elements, stimulating production of mRNA and induction of anti-inflammatory proteins, such as Annexin I. Non-genomic effects are not fully elucidated but are thought to be dose dependent. Inflammatory signals such as tumor necrosis factor-alpha, interleukin-1, microbial pathogens, and viral proteins activate membrane-bound receptors leading to degradation of inhibitor-kappa B and NF-κB release. In the absence of the GC-GR complex, NF-κB binds NF-κB elements in DNA sequences which activates the production of pro-inflammatory mediators and cyclooxygenase 2. The GC-GR complex directly binds NF-κB transcription factors causing repression of mRNA and inflammatory proteins. Adapted from Rhen 

Given the physiologic benefits derived from glucocorticoid activity, corticosteroids with glucocorticoid effects are preferred in ARDS. 15, 16 Methylprednisolone, a potent glucocorticoid, leads to increased concentrations in the lung compared to other corticosteroids due to its larger volume of distribution and tendency to be retained in the lungs for a longer period. [17] [18] [19] When used for ARDS, guidelines suggest weaning methylprednisolone over days to weeks because a rebound increase in pro-inflammatory cytokines may precipitate the recurrence of cytokine storm. 19 Recent clinical trials comparing dexamethasone to methylprednisolone in COVID-19 patients suggest greater benefit with methylprednisolone in terms of recovery time/length of hospital stay, intensive care need, and mechanical ventilation. [20] [21] [22] Of note, these trials used relatively higher doses of methylprednisolone compared to dexamethasone making it unclear if benefit is due to higher dose or corticosteroid selected. Dexamethasone, also a potent glucocorticoid, has a biological half-life up to 54 h allowing concentrations to auto-taper, decreasing the potential for a rebound effect upon discontinuation and need for a prolonged taper when treating ARDS. 23, 24 Corticosteroids with more potent mineralocorticoid effects, such as hydrocortisone, increase the expression of epithelial sodium channels and activate the basolateral Na + /K + ATPase pump in the distal portion of the nephron. This promotes sodium reabsorption and increases effective circulating volume, which may lead to pulmonary edema, worsening lung function, and increased duration of mechanical ventilation (MV). 25 ± 3 days HDCT vs. 6.8 ± 5.7 days placebo, p = 0.16) Patients alive at day 28 without organ support: (HCT 11.9 ± 9.7 days vs. placebo 9.5 ± 9.8, p = 0.13).

Within 30 hrs after ARDS onset DEX 20 mg IV daily days 1-5 10 mg IV daily days 6-10 Duration: 10 days or until extubation (if before 10 days)

Ventilator-free days at day 28: 12.3 (SD 9.9) DEX vs. control 7.5 (SD 9.0), p < 0.0001

All-cause mortality at 60 days: 29 (21%) DEX vs. 50(36%) control, p = 0.0047 Hospital mortality: 33 (24%) DEX vs. 50 (36%) control, p = 0.0235

A total of 360 articles were identified via database search after removing duplicates ( Figure 3 ). Full text of 25 articles were reviewed and 15 met inclusion criteria including 8877 patients. Data evaluated in these articles are in Tables 1 and 2 . RoB assessment was completed for all studies with 8 (53.3%) assessed to have low risk, 6 (40%) with some concerns, and 1 (6.7%) with high risk of bias (Table 3) Table 4 .

Standard of care for ARDS and management of MV have changed drastically across the time continuum of corticosteroid trials, influencing baseline mortality rates, and efficacy of co-interventions.

Outcomes studied have changed from Lung Injury Score (LIS) to difference in PaO 2 /FiO 2 and MV-free days (Table 1) . Controversy has continued in the role of corticosteroids in improving clinically meaningful outcomes like mortality, potentially due to overall sample sizes, differences in ARDS definitions, timing of corticosteroid initiation, dosing, and duration, and treatment crossover.

Bernard and colleagues studied the effects of high-dose methylprednisolone (30 mg/kg intravenously (IV) every 6 h for 24 h) on mortality in ARDS to understand the effect of corticosteroids on chest radiograph, oxygenation, and lung compliance. 29 Notably, there was no difference in the rate of mortality between the corticosteroid [60%; (95% CI, 46-74%)] and placebo groups [63%;

(95% CI, 49-77%)], with no difference during 45-day follow-up. In the subgroup analysis of patients with ARDS secondary to sepsis, patients treated with methylprednisolone had a lower reversal of chest radiograph and arterial blood gases vs. placebo (9% vs. 56%, p < 0.018) but no difference in survival. Contemporary ventilation practices recommend that patients with ARDS receive lung protective ventilation strategies; however, it is unlikely that such strategies were employed in this study. Criteria for reversal of blood gas were not fully elucidated, so we are unable to apply this finding to clinical practice. Furthermore, the study did not specify the duration, and frequency chest radiographs were evaluated for resolution of bilateral pulmonary edema.

In 1998, Meduri vs. 3/8, p = 0.03). The trial was stopped early and included a small sample size (n = 24). There were numerical differences in severity of illness at baseline between treatment and placebo groups. The study protocol allowed for crossover to the other treatment arm in patients who did not have a 1-point reduction in LIS by study day 10. Four patients in the placebo group crossed over to methylprednisolone but 0 patients in the methylprednisolone group crossed over.

This RCT evaluated the effects of hydrocortisone (200 mg loading dose IV followed by a 7-day infusion at 10 mg/h) on improvement in PaO 2 /FiO 2 , MODS score by study day 8, and reduction in septic shock. 31 

As early data demonstrating corticosteroid benefit were mixed using heterogeneous regimens, the ARDSNET trial attempted to better delineate the role of corticosteroids in ARDS on their primary outcome of 60-day mortality. 16 Patients were enrolled 7-28 days after the onset of ARDS and randomized to placebo or 3 weeks of IV methylprednisolone (2 mg/kg followed by 0. MV-free days. 33 The treatment group included more females, and a small percentage of total eligible patients were enrolled, bringing into question the generalizability of these results. 34

Annane and colleagues completed a post hoc analysis of their trial using hydrocortisone 50 mg IV every 6 h and enteral fludrocortisone 50 μg daily in patients with septic shock and relative adrenal insufficiency to assess the primary outcome of 28-day mortality. 35 Fifty-nine percent of the study population had mild ARDS (mean 

During initial stages of the COVID-19 pandemic, corticosteroids were not recommended for use due to previous evidence from the SARS and MERS outbreaks suggesting delayed viral clearance and worse outcomes. 39 Patients with COVID-19 often progress to systemic inflammatory response syndrome, furthering lung injury and damaging multiple organ systems which similarly to non-COVID-19 ARDS may be attenuated by anti-inflammatory properties of corticosteroids. 40, 41 Heterogeneous steroid regimens were studied among COVID-19 patients with a wide range of illness severity (Table 2 ).

The High a Some concerns: due to analysis excluding patients who exited the study, etc., and not intention-to-treat analysis.

b Some concerns: this was a post hoc analysis of an RCT due to the nature of not being pre-planned has some concerns for bias risk.

c Some concerns: mortality at day 21 was a post hoc outcome.

d Possible that missingness in outcome influenced by true value in patients who exited study due to adverse effects/ no information.

e Domain 5 assessed as some concerns as a result of trial being stopped prior to enough patients being enrolled to meet power; data were not analyzed in accordance with pre-specified analysis plan (domain 5.1). There were no multiple eligible outcome measurements (5.2) or analyses of the data (5.

3).

f Unclear if analysis was intent to treat. data were available for 99% of patients. There were 10 safety events reported in the corticosteroid arms, and one in the control arm;

however, details were not reported, and secondary infection rates are likely underreported (Table 4 ). This trial was halted early following release of RECOVERY findings. Limitations of this study include the unblinded treatment arms and up to 15% of the no-HCT group received a corticosteroid. Strengths include an intent-to-treat analysis of outcomes, including a primary analysis of corticosteroid-only patients.

The effect of hydrocortisone on 21-day mortality or respira- 

The COVID-19-associated ARDS treated with DEXamethasone 

The Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid) was a double-blind, randomized trial of hospitalized adult patients with suspected COVID-19 and randomized patients to receive methylprednisolone 0.5 mg/kg IV twice daily for 5 days to assess the primary outcome of 28-day mortality. 46 There was no difference in 28-day mortality between methylprednisolone and placebo (37.1% vs. 38.2%, p = 0.629), need for intubation (19.4% vs.

16.8%, p = 0.654), or hospital LOS (10 days vs. 9 days, p = 0.296).

Additionally, there was no difference in the need for insulin therapy, 

In their unblinded RCT, Jamaati and colleagues randomized 50 patients to receive dexamethasone 20 mg for 5 days, followed by 10 mg for 5 days vs. the control group in patients with mild-to-moderate ARDS. 47 Patients presented to the hospital a median of 8 days after symptom onset with randomization presumably on admission. The primary outcomes of invasive ventilation and 28-day mortality rate were studied with no difference in 28-day mortality (64% dexamethasone vs. 60% control, p = 0.500).

MV was needed in 13 (52%) of the dexamethasone group and 11 (44%) of the control, p = 0.389. Patients with chronic kidney disease, chronic liver disease, and those presenting with hyperglycemia were excluded in addition to its small sample size, limiting the generalizability of these findings. Additionally, it is unknown what effect other therapies (lopinavir/ritonavir 400/100 mg twice daily) may have had with no other studies included in our review using this concomitant therapy.

A recent triple-blinded RCT compared methylprednisolone vs.

dexamethasone for COVID-19. 20 Eighty-six patients were ran- 

As corticosteroids become more widely used for ARDS, consideration for adverse drug events is warranted. Short-term corticosteroid use is associated with hyperglycemia, behavioral disturbances, or cutaneous effects. 48 Long-term corticosteroid use may lead to weight gain, osteoporosis, and ocular and cardiovascular effects. 49 Critically ill patients may have increased risk of developing bacterial or fungal infections or stress-related mucosal damage. In general, corticosteroid regimens should be limited to the lowest dose over the shortest duration to limit these reactions. 50 Here, we describe short-term adverse drug events associated with corticosteroid use in COVID-19 ARDS and report adverse effects from the included studies in Table 4 and critical illness myopathy (CIM). ICU-AW may lead to prolonged MV, prolonged ICU, and hospital LOS, and mortality. 51, 52 The incidence of ICU-AW is reported to be 40%, with increased incidence in those with MV (65%), ARDS (60%), or sepsis (67%) and remains high at hospital discharge (36%), contributing to long-term disability among survivors. [52] [53] [54] [55] Corticosteroids are thought to contribute to ICU-AW through the breakdown of myosin and impairment of muscle membrane excitability. 51 A systematic review/meta-analysis found corticosteroid use was associated with increased odds of ICU-AW (OR 1.84; 95% CI 1.26-2.67; p = 0.002). 56 Those who received corticosteroids had higher overall incidence of ICU-AW compared to the control group (43% vs. 34%); however, these results may have been influenced by concurrent sepsis or use of MV.

Previous studies describing the additive risk for ICU-AW with concomitant use of corticosteroids and NMB must be interpreted with caution. Such studies evaluated corticosteroid doses higher than those used for ARDS in current practice. 57 These studies also evaluated aminosteroidal NMB rather than benzylisoquinoline NMB for prolonged durations. 58 More recent studies evaluating the combined effects of corticosteroids and NMB on ICU-AW have failed to show additive risk. 57,59

Viral diseases such as SARS and COVID-19 are associated with multiorgan dysfunction. Of particular concern are the effects seen on the pancreatic islet cells and resultant hyperglycemia. Acute hyperglycemia occurs in as many as 50% of hospitalized COVID-19

patients. 60 SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE-2) receptor to enter host cells. 61 An increase in ACE-2 receptors in the islet cells is associated with an increase in death, leading to an acute insulin-dependent diabetes mellitus state.

Corticosteroid-induced hyperglycemia is reported to be as high as 50% among those with no history of diabetes. 62 Tamez-Pérez and colleagues describe several mechanisms for hyperglycemia: (1) interference in signaling cascades in muscle or adipose tissue, leading to an insulinresistant state; (2) antagonism of insulin metabolic effects through induction of enzymes promoting gluconeogenesis, lipolysis, proteolysis, and nuclear peroxisome proliferator-activated receptor α; (3) enhancement of counterregulatory hormones (e.g., glucagon); (4) altered pancreatic beta cell function leading to reductions in insulin synthesis and secretion. 63 These mechanisms have been associated with a 30-50% reduction in insulin-stimulated glucose uptake and a 70% reduction in insulin-stimulated glycogen synthesis. The degree of hyperglycemia is thought to be dose dependent with intermediate-acting steroids (e.g., methylprednisolone) thought to have a shorter duration of hyperglycemia compared to long-acting steroids (e.g., dexamethasone). 64 

Corticosteroid administration brings forth a double-edged sword of concern in the COVID-19 pandemic. Corticosteroids induce an immunosuppressed state through sequestration of CD4 + T cells and inhibition of cytokine transcription. 65 Chronic use has been associated with reduction in natural killer cells and complement pathway activation. 66 Additionally, reduced reactive oxygen species production and increased pro-inflammatory cytokine release (e.g., IL-6 and tumor necrosis factorα) combined with an increase in apoptosis leading to fewer T and B cells may increase the risk of infection.

Among those with COVID-19, the risk of secondary infection from corticosteroid use may be as high as 25% for bacterial and 12.7% for fungal infections. 67 (Table 4 ). Of particular concern with corticosteroid use is the potential for fungal or opportunistic infections. Fungal infections in SARS had an incidence of 33% in severe disease and fungal infection-associated mortality in 73.7%

of cases. 69 The risk for fungal infections should not be minimized, with the rate of presumed invasive pulmonary aspergillosis reported as high as 19.4% among COVID-19 admitted patients. 70 One patient in the REMAP study developed fungemia that the authors associated with hydrocortisone; otherwise fungemia was not reported in the other included trials. 43 In addition to fungal disease, infection due to strongyloidiasis is also of concern. 71,72

3.18.4 | Central nervous system 

Given the mixed findings from trials evaluating the use of corticosteroids in ARDS, and variability of regimens, the decision of whether, when, and how to initiate corticosteroids for ARDS should be patient specific. Prior to the DEXA-ARDS trial, previous guidelines evaluating the use of corticosteroids in non-COVID-19

ARDS stated the evidence was insufficient while other guidelines recommend corticosteroid use for early management of non-COVID-19-ARDS and warn of potential harm when starting methylprednisolone greater than 14 days from symptom onset. 16, 19, 78 Corticosteroids may have a positive disease-modifying effect and benefits of therapy may outweigh the risk of adverse effects.

However, in critically ill patients with COVID-19 ARDS, benefits of corticosteroids have been clearly reported, and therefore use is recommended in this subset of patients. [79] [80] [81] The studies included in our review found mortality benefit in 6/15 (40%) studies with benefit being seen at varying time points (ICU survival, hospital, and 28 and 60 days) in the COVID-19 and non-COVID-19 studies.

One non-COVID-19 ARDS trial found an increased risk of mortality at both 60 and 180 days in patients receiving methylprednisolone greater than 14 days after the onset of ARDS. 16 Interestingly, studies showing 28-day mortality benefit in COVID-19 were the largest trial (RECOVERY), and a post hoc analysis of patients >60 years old in the Metcovid trial. These findings align with a meta-analysis finding all-cause mortality benefit with the use of corticosteroids for COVID-19 ARDS. 80 The two non-COVID-19 trials assessing LIS improvements found significant improvements with corticosteroid use. 30, 32 The four non-COVID-19 ARDS trials assessing MV-free days found a significant increase in MV-free days compared to placebo. 16, 31, 32, 35 The increase in MV-free days has been previously supported in a meta-analysis of RCTs using corticosteroids for ARDS patients. 81 This systematic review included data from RCTs and assessment of bias was completed with the RoB 2.0 tool strengthening our review. Additionally, the majority of included studies were multicenter and many were blinded. however, a small RCT found greater benefit with methylprednisolone over dexamethasone. 20, 42 Perhaps this variability exists because the optimal regimen has not yet been studied in large, prospective, blinded, RCTs. Additionally, enrichment strategies using ARDS subphenotypes should be considered in future trials. Such data may better determine corticosteroid benefit for the right patient, using the right drug, and at right dose. 82 

Corticosteroids have been shown to improve mortality and MV-free days in both COVID-19 and non-COVID-19 ARDS, with evidence suggesting their use in these settings. 39, [77] [78] [79] [80] Vigilant monitoring to promote the safe and effective use of corticosteroid dosing, duration, and drug selection is necessary.

The authors declare no conflicts of interest. 

Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries

Acute respiratory distress syndrome

Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey

Comparing clinical features and outcomes in mechanically ventilated patients with COVID-19 and the acute respiratory distress syndrome

Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 infection is morphologically indistinguishable from other causes of DAD

Antiinflammatory action of glucocorticoidsnew mechanisms for old drugs

Corticosteroids and ARDS: a review of treatment and prevention evidence

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Molecular mechanisms of glucocorticoid action: what is important?

Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors

Induction of cytokine receptors by glucocorticoids: functional and pathological significance

Corticosteroids in acute lung injury: the dilemma continues

Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS

Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults

Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome

Penetration of corticosteroids into the lung: evidence for a difference between methylprednisolone and prednisolone

Methylprednisolone achieves greater concentrations in the lung than prednisolone: a pharmacokinetic analysis

Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia

A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19

Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations

Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019

Mineralocorticoid receptor antagonists: a comprehensive review of finerenone

Comparison of two fluid-management strategies in acute lung injury

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

RoB 2: a revised tool for assessing risk of bias in randomised trials

High-dose corticosteroids in patients with the adult respiratory distress syndrome

Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial

Hydrocortisone infusion for severe community-acquired pneumonia

Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial

An exploratory reanalysis of the randomized trial on efficacy of corticosteroids as rescue therapy for the late phase of acute respiratory distress syndrome*

Corticosteroids in ARDS

Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome

Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial

Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

COVID-19) Treatment Guidelines. National Institutes of Health

Cytokine storm intervention in the early stages of COVID-19 pneumonia

Association of elevated inflammatory markers and severe COVID-19: a meta-analysis

Dexamethasone in hospitalized patients with Covid-19 -preliminary report

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19

Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, Placebo-controlled trial

No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial

Side effects of corticosteroid therapy

Population-based assessment of adverse events associated with long-term glucocorticoid use

Intensive care unit-acquired weakness

Molecular mechanisms of intensive care unit-acquired weakness

The incidence of intensive care unit-acquired weakness syndromes: a systematic review

Critical illness polyneuropathy and myopathy in patients with acute respiratory distress syndrome*

An Official American Thoracic Society Clinical Practice Guideline: the diagnosis of intensive care unit-acquired weakness in adults

Corticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis

Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials

Corticosteroids and neuromuscular blockers in development of critical illness neuromuscular abnormalities: a historical review

Neuromuscular blockers in early acute respiratory distress syndrome

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment

Corticosteroid-induced hyperglycemia

Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: a narrative review

Glucocorticoid-induced hyperglycemia

Pharmacologic immunosuppression

Glucocorticoid excess and COVID-19 disease

Increased secondary infection in COVID-19 patients treated with steroids in New York City

Bacterial and viral coinfections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU

Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China

Interactions of cryoprotective agents with phospholipid membranes -a Langmuir monolayer study

Report: Disseminated strongyloidiasis in a patient with COVID-19

Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia

Corticosteroid-related central nervous system side effects

Prednisone effects on neurochemistry and behaviour. Preliminary findings

Central nervous system effects of natural and synthetic glucocorticoids

Considerations for postacute rehabilitation for survivors of COVID-19

Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study

Guidelines on the management of acute respiratory distress syndrome

Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials

Identification of distinct clinical subphenotypes in critically ill patients with COVID-19

Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID-19): A systematic review